Ironwood Pharmaceuticals

IRWD

Market cap $586M

Ironwood and Puma Biotechnology are advancing therapies for gastrointestinal disorders and cancer, respectively. Rising sales of key drugs fuel 2026 prospects.

Ironwood Pharmaceuticals (IRWD) remains undervalued despite a failed $1bn Vectiv Bio acquisition and subsequent stock plunge, with Linzess providing strong recurring revenue. IRWD's apraglutide Phase 3 trial met primary endpoints but failed to surpass Takeda's Gattex, prompting the FDA to require another confirmatory study before approval. Linzess sales are robust, with Q3 2025 sales up 40% year-on-year and new pediatric approval, but looming 2029 patent expiry poses a long-term risk.

Ironwood gains momentum as rising U.S. demand for Linzess drives strong profit growth during the third quarter.

Ironwood's 110% monthly surge follows upbeat third-quarter results and raised 2025 outlook, powered by increasing Linzess demand.

Ironwood posts a stellar third-quarter beat with higher revenues and raises 2025 outlook on Linzess-driven strength.

Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.02 per share a year ago.

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its third quarter 2025 results and recent business performance. “LINZESS delivered a strong third-quarter performance, driven by accelerated double-digit prescription demand growth combined with improved net pricing, which prompted us to raise our full-year 2025 financ.

CALGARY, AB / ACCESS Newswire / October 24, 2025 / Ironwood Stair & Rail Inc., a company built on craftsmanship and passion, has been recognised with the 2025 Consumer Choice Award in the Stairs and Railings category for Southern Alberta. This recognition highlights Ironwood's reputation for exceptional design, quality, and service in transforming homes and businesses with custom-built stairs and railings.

Innovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may prove to be good additions to one's portfolio.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.